Suppr超能文献

国家监测脑瘫儿童口服用药处方

National surveillance of oral medication prescription for children with dystonic cerebral palsy.

机构信息

Neurodisability and Rehabilitation, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.

Neurodevelopment and Disability, Royal Children's Hospital, Melbourne, Victoria, Australia.

出版信息

J Paediatr Child Health. 2021 Aug;57(8):1222-1227. doi: 10.1111/jpc.15429. Epub 2021 Mar 3.

Abstract

AIM

Oral medications are often first-line medical management for children with cerebral palsy who have generalised dystonia; however, evidence for their effectiveness is limited and dosing practices are inconsistent. As a first step to improve consistency, this study aimed to examine current clinical practice of expert doctors for prescribing medications for children with dystonic cerebral palsy including prescribing patterns and combinations of medications used.

METHODS

This was a prospective surveillance study of medical doctors working in major Australian centres who manage children with cerebral palsy. Each week over a continuous 6-month period, doctors completed a custom developed online survey for children seen that week with dystonic cerebral palsy for whom they prescribed a new medication to treat dystonia.

RESULTS

Twenty-five doctors consented to participate, 16 of whom prescribed new medications for dystonia in children with cerebral palsy over the study period. There were 77 children who were prescribed new medications. Baclofen and gabapentin were prescribed most, followed by levodopa, trihexyphenidyl and diazepam. The most common combinations of medications were baclofen and diazepam or baclofen and gabapentin. Dosage regimens were variable, particularly for trihexyphenidyl and diazepam.

CONCLUSION

Inconsistencies in dosing regimens remain for oral medication prescription by Australian doctors when managing dystonia in cerebral palsy. Future studies using the consensus of expert clinicians will be conducted to develop guidelines in an area where the evidence for individual medications is extremely limited.

摘要

目的

对于患有全身性肌张力障碍的脑瘫儿童,口服药物通常是一线医学治疗方法;然而,其疗效的证据有限,且剂量用法不一致。作为提高一致性的第一步,本研究旨在检查专家医生为患有肌张力障碍性脑瘫的儿童开处方药物的当前临床实践,包括开出处方模式和使用的药物组合。

方法

这是一项针对在澳大利亚主要中心管理脑瘫儿童的医生的前瞻性监测研究。在连续 6 个月的每周内,医生都会为本周就诊的新诊断为脑瘫且伴有肌张力障碍的儿童填写一份定制的在线调查问卷,内容涉及为其开的新治疗肌张力障碍的药物。

结果

25 名医生同意参与研究,其中 16 名在研究期间为脑瘫伴有肌张力障碍的儿童开了新的肌张力障碍治疗药物。共有 77 名儿童被开具了新的药物。巴氯芬和加巴喷丁的开出处方最多,其次是左旋多巴、苯海索和地西泮。最常见的药物组合是巴氯芬和地西泮或巴氯芬和加巴喷丁。剂量方案各不相同,特别是苯海索和地西泮。

结论

澳大利亚医生在治疗脑瘫性肌张力障碍时,口服药物的剂量方案仍存在不一致性。未来将使用专家临床医生的共识进行研究,以制定在个体药物证据极为有限的领域的指南。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验